Comparison of so-called variables in these two groups did not indicate any statistically significant difference but for variceal bleedings in case group (p-value: 0.013, OR: 2.526, 95% CI: 1.200–5.317). Conclusion: The aetiology of PVT in cirrhotic patients is not clear. Medical interventions such as treatment of variceal bleeding rather than genetic factors may have the most important LY2606368 research buy role. Key Word(s): 1. Portal Vein; 2.

Liver Cirrhosis; 3. Risk factor; 4. Thrombosis; Presenting Author: ALLAERT FRANCOIS Corresponding Author: ALLAERT FRANCOIS Objective: Objectives: In association with lifestyle recommendations and alcohol intake reduction, to evaluate versus placebo the improvement of the hepatic function (main objective) induced by Han Hepa® (plants extracts and nutriments among which Lycium Chinense) and of cardiovascular risk factors (secondary objectives) in which hepatic metabolism is involved. Kinase Inhibitor Library mw Methods: Design: controlled, double blind, randomised versus placebo study. Inclusion criteria: patients older than 18, presenting an increase of the transaminases (ALAT and ASAT) >2 times the value of reference. The main criteria was the ASAT and ALAT

plasmatic values which reflect hepatocytes cytolysis. The secondary criteria: the alkaline phosphatases, the Total, HDL and LDL cholesterol and the triglycerides. Patients were followed up during 12 weeks. Results: 46 patients (24 in the Han Hepa® group (HHG) and 22 in the placebo group (PlG) were included. After 12 weeks, results show a statistically higher decrease of the ALAT in the HHG than in the PlG: −44.3 ± 47.8 vs −8.5 ± 65.4 (p:0.0389) corresponding respectively to reductions of 39.4% and 9.5% of the inclusion values which is significant (p < 0.0001) in the HHG and not in the PlG (p:0.5465). A decrease of at least 50% of the ALAT is present in 41.7% of the HHG versus in 18.2% of the PlG (p:0.08). A statistically higher decrease of the ASAT in the HHG than in the PlG is also observed: −50.7 ± 65.0 vs −9.6 ± 37.6 (p:0.0129) corresponding respectively to

reductions of 50.2% and Diflunisal 13, 7% of the inclusion values which are significant (p: 0, 0009) in the HHG and not in the PlG (p:0.2430). A decrease of at least 50% of the ASAT is present in 41.7% of the HHG versus in 13.6% of the PlG (p = 0, 03). GGT decrease also more in the HHG than in the PlG : −43, 7 ± 73, 4 vs 15, 5 ± 121, 1 (p:0.0525). By contrast, the evolution of the alkaline phosphatases, of the Total, HDL and LDL cholesterol and of the triglycerides are not significant either inside each group and between groups. Conclusion: In association with lifestyle recommendations an especially concerning alcoholic consumption reduction, Han Hepa® contributes to significantly restore the hepatic function. Key Word(s): 1. liver; 2. hepatic; 3. food supplement; 4.